Company / R&D Expense
Dynavax Technologies Corp. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$61.5M
FY2024
5-year range
$28.6M / $61.5M
FY2020-FY2024
Trend
+12.1%
vs FY2023
Sector context
#172 of 209
Health Care
What the data says
Dynavax Technologies Corp.'s r&d expense of $62M is lower than 82% of companies in the Health Care sector (FY2024). R&D Expense has increased for 4 consecutive years, from $29M in FY2020 to $62M in FY2024.
Based on SEC 10-K filings.
$62M in FY2024 with a 5-year CAGR of -0.3%.
Improved from $47M to $62M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- -0.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 209This company $61.5M Sector average $647.6M
▼
-90.5% below sector average
Key checks
Key Insights
- Dynavax Technologies Corp.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of -0.3%, indicating a declining trend.
- In FY2024, r&d expense increased 12.1% year-over-year.
- Ranks #172 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $61.5M | +12.1% |
| FY2023 | $54.9M | +17.8% |
| FY2022 | $46.6M | +44.6% |
| FY2021 | $32.2M | +12.7% |
| FY2020 | $28.6M | -54.1% |
| FY2019 | $62.3M | -16.8% |
| FY2018 | $75.0M | +15.3% |
| FY2017 | $65.0M | -23.1% |
| FY2016 | $84.5M | -2.8% |
| FY2015 | $86.9M | +2.8% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026